This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche Submits Application for Tecentriq-Avastin Combo in HCC
by Zacks Equity Research
Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
Roche's Urothelial Cancer Study on Tecentriq Disappoints
by Zacks Equity Research
Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.
Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma
by Zacks Equity Research
Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
by Kinjel Shah
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children
by Zacks Equity Research
Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
BioLineRx Concludes Recruitment in Pancreatic Cancer Study
by Zacks Equity Research
BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
Roche's Risdiplam Meets Primary Endpoint in Infants Study
by Zacks Equity Research
Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.
How Does This Frothy Stock Market Run End?
by John Blank
This is a question worth answering, with care.
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza
by Zacks Equity Research
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
by Zacks Equity Research
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
The Zacks Analyst Blog Highlights: Roche, Royal Dutch Shell, Citigroup, UnitedHealth and Costco Wholesale
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Royal Dutch Shell, Citigroup, UnitedHealth and Costco Wholesale
Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe
by Zacks Equity Research
Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.
Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding (RHHBY), Royal Dutch Shell (RDS.A) and Citigroup (C).
Seattle Genetics Up More Than 40% in the Past Year: Here's Why
by Zacks Equity Research
Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.
AstraZeneca Announces Positive FDA Updates on Cancer Drugs
by Zacks Equity Research
AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver cancer.
Snap Up 5 Mega-Cap Stocks with Impressive Growth Prospects
by Nilanjan Choudhury
Mega-caps, usually the largest and most established companies in the stock market, tend to be stable, and many of them pay dividends based on their earnings.
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M
by Zacks Equity Research
Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.
Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).
Where Is the Top to This Stock Market Run? Zacks JAN Strategy
by John Blank
It is commonplace to acknowledge the role of the U.S. Fed lifting stock markets the last three months. But earnings outlooks drawn up on the last quarter of 2019 are not improving.
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
by Zacks Equity Research
Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study
by Zacks Equity Research
Exelixis (EXEL) plans to further expand the metastatic CRPC cohort of the phase Ib study on lead drug, Cabometyx.
Blueprint Medicines Initiates Dosing in Liver Cancer Study
by Zacks Equity Research
Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.
Horizon Therapeutics' Stock Up in a Year on Pipeline Progress
by Zacks Equity Research
Horizon Therapeutics' (HZNP) shares have risen in the past year owing to the development of its pipeline candidates.